Basit öğe kaydını göster

dc.contributor.authorArda-Pirincci, Pelin
dc.contributor.authorAykol-Celik, Guliz
dc.date.accessioned2021-03-05T17:37:06Z
dc.date.available2021-03-05T17:37:06Z
dc.date.issued2020
dc.identifier.citationArda-Pirincci P., Aykol-Celik G., "Galectin-1 reduces the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis by suppressing inflammatory and oxidative stress response", BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, cilt.20, ss.319-328, 2020
dc.identifier.issn1512-8601
dc.identifier.otherav_c66d3973-47dc-4fb1-9b65-66c25c55566a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/131555
dc.identifier.urihttps://doi.org/10.17305/bjbms.2019.4539
dc.description.abstractUlcerative colitis is an inflammatory bowel disease that affects a large number of people around the world. Galectin-1 is a beta-galactoside-binding lectin with a broad range of biological activities. The effects of galectin-1 on dextran sulfate sodium (DSS)-induced ulcerative colitis in vivo is not clear. We investigated the effect of galectin-1 on colon morphology, cell proliferation, oxidative stress, antioxidant system, and proinflammatory/antiinflammatory cytokines in a DSS-induced mouse model of ulcerative colitis. Thirty-two C57BL/6 mice were randomly assigned to one of the four groups: control, acute colitis, galectin-1, and DSS+galectin-1. Controls were treated with phosphate-buttered saline (PBS) for seven days. Acute colitis was induced by 3% DSS in drinking water administered orally for five days. Mice in galectin-1 groups were treated with 1 mg/kg recombinant human galectin-1 in PBS for seven consecutive days. Oral DSS administration resulted in acute colitis by causing histopathological changes; an increase in disease activity index (DAI), lipid peroxidation (malondialdehyde MDA]), myeloperoxidase (MPO), and tumor necrosis factor (TNF)-alpha levels; a decrease in body weight, colon length, cell proliferation index, catalase, glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities, and GSH and interleukin (IL)-10 levels. The treatment with galectin-1 attenuated DSSinduced acute colitis by reducing DAI, MDA, MPO, and TNF-alpha levels and by increasing body weight, colon length, cell proliferation, antioxidant enzyme activity, GSH, and IL-10 levels. These findings suggest that galectin-1 has proliferative, antioxidant, antiinflammatory, and cytoprotective effects against DSS-induced ulcerative colitis in mice. Due to its antiinflammatory and antioxidant activity galectin-1 may be effective in preventing and treating ulcerative colitis.
dc.language.isoeng
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.titleGalectin-1 reduces the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis by suppressing inflammatory and oxidative stress response
dc.typeMakale
dc.relation.journalBOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
dc.contributor.departmentİstanbul Üniversitesi , Fen Fakültesi , Biyoloji Bölümü
dc.identifier.volume20
dc.identifier.issue3
dc.identifier.startpage319
dc.identifier.endpage328
dc.contributor.firstauthorID2275648


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster